Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies.
We performed a cost-utility analysis for various vaccination strategies against meningococcal and pneumococcal diseases (MenC or MenC/PCV-9) in Switzerland. The analysis compared the current recommendations of vaccinating only children with medical risks to the introduction of the vaccination with either the MenC or the MenC/PCV-9 vaccine, administered at 12 or 2, 4 and 6 months of age, into the existing immunisation programme. For a birth cohort of 80,000 children and assuming a vaccine coverage of 80%, the introduction of a generalised vaccination would be cost-effective. The strategy using three doses of MenC/PCV-9 would achieve the highest health benefit, with 440 quality-adjusted life years (QALYs) gained at costs of 34,000 per QALY.
D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D007223:Infant; D032541:Mass Vaccination / Q000191:economics; D008589:Meningococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000191:economics*; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000276:immunology*; D013557:Switzerland / Q000453:epidemiology
D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines